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Abstract
Background
Until recently, circulating micro-RNAs (miRNAs) have attracted major interest as novel
biomarkers for the early diagnosis of coronary artery disease (CAD). This review article
summarizes the available evidence on the correlation of micro-RNAs with both the clinical and
subclinical coronary artery disease and highlights the necessity for exploring miRNAs as a
potential diagnostic and prognostic biomarker of early CAD in an adult population.
Methods
A systematic literature analysis and retrieval online systems Public/Publisher MEDLINE/
Excerpta Medica Database /Medical Literature Analysis and Retrieval System Online,
(PUBMED/EMBASE/MEDLINE) search were conducted for relevant information. Search was
limited to the articles published in English language and conducted on humans, January 2000
onwards. We excluded studies of heart surgery, coronary artery bypass grafting (CABG),
angioplasty and heart transplant. Eighteen studies met the inclusion criteria.
Results
Seven out of 18 studies were multivariate, i.e. adjusted for age, gender, body mass index (BMI),
smoking, hypertension, diabetes, and blood lipid profiles, while the remaining twelve studies
were univariate analysis. Different sources of miRNAs were used, i.e. plasma/serum,
microparticles, whole blood, platelets, blood mononuclear intimal and endothelial progenitor
cells were investigated. Fourteen out of 18 studies showed up-regulation of different miRNA in
CAD patients and in vulnerable plaque disease. Four out of 18 studies showed both the up-
regulation and down-regulation of miRNA in the population, while only three studies showed
down-regulation of miRNA. Various sources and types of miRNA were used in each study.
Conclusion
1 2 2 2
2 2 2 3 4
5 2 6 7 8
2
 Open Access OriginalArticle  DOI: 10.7759/cureus.1188
How to cite this article
Malik R, Mushtaque R S, Siddiqui U A, et al. (April 23, 2017) Association Between Coronary Artery
Disease and MicroRNA: Literature Review and Clinical Perspective. Cureus 9(4): e1188. DOI
10.7759/cureus.1188
This review gives an extensive overview of up-regulation and down-regulation of miRNA in
CAD and non-CAD patients. The pattern of miRNA regulation with respect to CAD/non-CAD
study subjects varies across individual studies and different parameters, which could be the
possible reason for this aberrancy. We suggest further trials be conducted in future for
highlighting the role of miRNA in CAD, which may improve both the diagnostic and therapeutic
approaches to stratifying CAD burden in the general population.
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Introduction
Heart disease is the leading cause of death for both males and females with more than half of
the deaths reported in 2009 in males [1]. Coronary heart disease is the most common type of
heart disease with 370,000 annual deaths, i.e. each minute someone in the United States dies
from a heart disease-related event [2]. Coronary heart disease alone each year costs the United
States $108.9 billion, which includes the cost of health care services, medications, and lost
productivity [3]. The total coronary artery disease (CAD) prevalence is 6.4% in US adults, which
is expected to increase approximately 18% by 2030 [4]. Most individuals aged over 60 years have
progressively enlarged deposits of calcium mineral in the plaques in their major arteries [5]. As
atherosclerosis infiltrates the arterial wall long before it causes vessel obstruction and produces
symptoms, earlier identification of this process should be part of risk prediction [6]. As such,
there is a lack of cost-effective and specific biomarkers for the early clinical diagnosis and
prognosis of CAD, and there is an immense clinical demand for specific and reliable non-
invasive biomarkers for CAD.
With over 1900 MicroRNA (miRNAs) discovered in humans to date, many of them have already
been implicated in common human disorders. However, the pattern among the miRNA-disease
association remains largely unclear for most diseases. Until recently, circulating micro-RNAs
(miRNAs) have attracted major interest as novel biomarkers for the early diagnosis of CAD [7].
MiRNAs are a class of small (~22 nucleotides long), highly specific, endogenous, single-
stranded, non-coding RNAs that regulate the expression of target genes by binding to the 39
untranslated regions and degrading or inhibiting the translation of messenger ribonucleic acid
(RNA) (mRNAs) [8]. Studies have shown miRNAs' involvement in the timing of cell death and
cell proliferation, hematopoiesis, and other normal cellular homeostasis [9-10]. Various
miRNAs are expressed in a tissue-specific manner and thus may regulate tissue-specific
functions. This review article summarizes the available evidence correlating micro-RNA,
clinical and subclinical CAD and further highlights the necessity for exploring the potential of
micro-RNAs as useful diagnostic and prognostic biomarkers for early CAD in the adult
population.
Materials And Methods
A computerized search of the Public/Publisher MEDLINE/ Excerpta Medica Database /Medical
Literature Analysis and Retrieval System Online/Excerpta Medica Database
(PubMed/Medline/EMBASE) database was done with the keywords and medical subject
headings (MESH) terms such as “micro RNA,” “coronary artery disease,” “cardiovascular disease
(CVD),” “Subclinical CVD,” “coronary artery calcium and micro RNA,” "miRNA and high
sensitivity C- reactive protein (hs-CRP),” “miRNA and coronary intimal thickness,” and
“miRNA and pulse wave velocity.” We included all the literature that was published from
January 1, 2000, until January 1, 2017. The search was limited to articles published in the
English language. Included studies were cross-sectional, case-control or prospective in design
and conducted in adult populations (Figure 1). CAD subjects diagnosed by symptoms, imaging,
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cardiac enzymes, electrocardiogram (EKG), diagnostic angiography or stress testing were
included. We excluded studies with CAD patients who have had heart surgery, coronary artery
bypass graft (CABG), angioplasty, and heart transplant. We also examined the references of all
studies from the initial search for additional references. Demographic data was extracted from
each study and results were collaborated into tables.
FIGURE 1: Detailed literature analysis- CAD and miRNA
association
Results
A total of 18 clinical studies has been included in the review after a thorough analysis of the
literature. Overall, there were 1720 subjects. The majority of the studies included were done in
China, which was 11 in number, while two studies from Japan, one from the USA, one from
Norway, one from Netherlands, one from the UK and one from Germany were included (Table
1). All the studies had the same outcome, which was CAD. Studies were further divided into two
groups of microRNA up-regulation and down-regulation. There were four studies that checked
for both up-regulation and down-regulation of microRNA. 
Type
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Serial# Author, Year,  Study
Population
Study Population Characteristics Country of
Study
Outcome
1 Diehl, et al.,2011 [8]; CAD(n=5), ACS (n=5)
CAD: A: 76±2; M: 3 (60%)                          ACS: A:
66±4; M 5 (100%) China
Case
Control CAD
2 Sayed, et al., 2015 [11]; CAD(n=65),  Non-CAD (n=32)
CAD: A: 53 (49–57); M: 38 (58.4%) Non-CAD: A: 53
(49–57); M: 16(50%) China
Case
Control CAD
3 Sayed, et al., 2015 [12]; CAD(n=37),  Non-CAD (n=20)
CAD: A: 72.97 ± 4.28; M: 18 (67.5%) Non-CAD: A:
71.7 ± 5.2, M: 10(50%) China
Case
Control CAD
4 Zhou, et al., 2015 [13]; CAD(n=67),Non-CAD (n=67)
CAD: A 64.70± 6.79 M: 43 (64.2%) Non-CAD: A:
63.69± 5.96 M: 32 (47.8%) China
Case
Control CAD
5 Liu, et al., 2015 [14];CAD(n=90),  Non-CAD (n=70) Not Given China
Case
Control CAD
6 Han, et al., 2015 [15]; CAD(n=32), Non-CAD (n=20)
CAD A: 67±11; M: 32 (100%) Non-CAD: A 62±8; M:
20 (100%) China
Case
Control CAD
7 Zhu, et al., 2014 [16];CAD(n=56), Non-CAD (n=54) Not Given China
Case
Control CAD
8 Li, et al., 2013 [17];  Pre-CAD(n=12), Non-CAD (n=12) Age/Sex matched in pre CAD and Non CAD. China
Case
Control CAD
9 Ren, et al., 2013 [18]; CAD(UA) (n=45), Non-CAD (n=37)
CAD (UA): A: 63±12; M: 25 (55.5%) Non-CAD:
59±6, M: 22 (59.4%) China
Case
Control CAD
10
Guo, et al., 2012 [19];
HLD+CAD (n=155), non-HLD
(n=100)
HLD+CAD: A: 65.3 ± 11.0; M:  105 (67.7%) Non-
CAD: A 63.0 ± 10.7; M: 35 (70%) China
Case
Control CAD
11
Weber, et al., 2011 [20];
CAD (n=10), Non-CAD
(n=15)
Age and sex matched USA CaseControl CAD
12
Sondermeijer, et al., 2011
[21]; Pre CAD (n=40), Non-
CAD (n=40) ASCL (n=27),
family(n=40)
Age matched and males only; controls > 20 yr
younger, sex unknown Netherlands
Case
Control CAD
13
Fichtlscherer, et al., 2011
[22];CAD (n=67), Non-CAD
(n=31)  
Cohort; CAD: A: 67.69 ± 11.07; M: 25 (69.4%)
Non-CAD: A: 32.18 ± 8.78Male: 6 (35.3%); VC;
CAD: A: 68.06 ± 9.66; M: 21 (68%) Non-CAD: A:
39.28 ± 17.52; M: 5: (36%)
Germany CaseControl CAD
14  
Taurino, et al., 2010 [23];
CAD (n=12), Non-CAD
(n=12)
CAD: A: 66±11; M: 12 (100%) Non-CAD: A: 59 7;
M: 12 (100%) UK
Case
Control CAD
15
Hoesktra, et al., 2010 [24]; 
UAP (n=25), SAP (n=25),
Non- CAD (n=20)
Age, sex, ethnically, smoking matched Norway CaseControl CAD
Takahashi, et al., 2010 [25];
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Serial
#  
Name of
Author; Year
of Study
MicroRNA
(miR or
miRNA)
MicroRNA:
Regulation
MicroRNA
Analysis  Source
Strength of
Association (Odds
ratio, Relative Risk or
Regression  Analysis)
   
Comments
1 Diehl, et al.2012 [8]
miR 19 miR
21 miR 146
miR 155
miR 223
Up-
regulated:
miR 19
miR 21
miR 146
 miR 155
miR 223
QRT-PCR
MP
 from
plasma
ACS vs CAD      miR
21 P=0.042 miR 146a
P=0.003
Univariate Analysis
2   Sayed, etal., 2015 [11]
miR149 miR
424 miR
765
Up-
regulated:
miR 765    
QRT-PCR Serum/Plasma
Non-CAD vs. CAD
(Adjusted) miR 149
95% CI  0.894 to 0.983
p= <0.0001 miR 424
95% CI  0.863 to 0.975
p = <0.0001 miR 765 
Adjusted for age,
gender, TC, TAG, HDL-
C, LDL-C, systolic blood
pressure, diastolic blood
pressure, AST, ALT,
creatinine, LVEF, DM,
16 Stable CAD (n=66), Non-
CAD (n=33)
CAD: A: 66.2±9.5, M: 52 (79%) Non-CAD: A:
64.2±10.3, M: 26 (79%)
Japan Case
Control
CAD
17 Li, et al., 2010 [26]; AO(n=104), Non-AO (n=105) Age Matched China
Case
Control CAD
18
Minami, et al., 2009 [27];
Stable CAD (n=44), Non-
CAD (n=22)
CAD: A 66.1±12.8; M: 36 (82%). Non-CAD: A: 64.5
± 8.5, M: 17 (77%)  Japan
Case
Control CAD
TABLE 1: Demographics table
A :Age, M: Male, CAD: Coronary Artery Disease, AP: Atherosclerotic Plaque, Pre: Premature, UA: Unstable Angina, HLD:
Hyperlipidemia, ACS: Acute Coronary Syndrome, ASCL: Atherosclerosis, VC: Validation Cohort, UAP: Unstable Angina Pectoris,
SAP: Stable Angina Pectoris, AO : Arteriosclerosis Obliterans
Up-regulation and microRNA
A total of 15 studies reported up-regulation of micro RNAs in patients with CAD. Ten
studies out of the 15 used plasma as the source while two studies used peripheral blood
mononuclear cells as the source, one study used microparticles (MP) from plasma, one
study used endothelial progenitor cells (EPC) and one study used platelets. The majority of
the studies employed quantitative reverse transcription polymerase chain reaction (QRT-
PCR) for mircoRNA analysis while only one study employed Kyoto encyclopedia of genes
and genomes (KEGG) method for microRNA analysis (Li, et al. 2013). All studies reported
that there is up-regulation of specific miRNA in relationship to CAD. Univariate analysis
was done in nine of the 15 studies, while remaining studies adjusted for age, sex, high-
density lipoprotein (HDL), low-density lipoprotein (LDL), aspartate aminotransferase (AST),
alanine aminotransferase (ALT), hypertension HTN etc in their analysis (Table 2).
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95% CI  0.939 to 0.996
p=0.0001
smoking, HTN and
medications
3 Sayed, et al.,2015 [12]  
miR 149
miR 765
Up-
regulated:
miR 765    
QRT-PCR Serum/Plasma
Stable/unstable CAD
vs Non-CAD 
(Adjusted) miR 765  p=
< 0.001
Adjusted for subjects
with similar age, gender,
total cholesterol, total
glyceride, HDL, LDL,
systolic blood pressure,
diastolic blood pressure,
AST, ALT, creatinine,
cardiac troponinI, CK-
MB, LDH, LVEF, DM,
smoking, HTN, and
medications
 4 Zhou, et al.,2015 [13]
miR206
miR574/5p
Up-
regulated:
miR 206
miR
574/5p    
QRT-PCR Plasma
CAD vs Non-CAD
(Adjusted) miR 206 –
95% CI: (0.508-0.706)
miR 574/5p – 95% CI:
(0.609- 0.787)
Multivariate analysis (no
significant differences
between two groups
including HTN, DM,
smoking history, age,
gender, HDL-C, TAG,
LDL-C and TC)
 5 Liu, et al.,2015 [14]
miR 2861
miR 3135b
miR191/3p
miR133a/3p
miR1229/5p
miR134
miR3679/5p
miR223
Up-
regulated:
miR
133a/3p
miR 134
miR
191/3p
miR 223
miR
1229/5p
miR 2861
miR 3135b
miR
3679/5p
QRT-PCR Serum/Plasma
Unadjusted miR
133a/3p 95% CI 0.55-
0.82 p = 0.0096 miR
134 95% CI 0.54-0.82
p= 0.015 miR 191/3p
95% CI 0.58-0.83p=
0.0046 miR 223 95%
CI 0.47-0.74p= 0.13
miR 1229-5p 95% CI
0.54-0.83 p= 0.015
miR  286195% CI
0.61-0.87 p= <0.001
miR  3135b95% CI
0.61-0.86 p= <0.001
miR 3679/5p95% CI
0.49-0.79  p = 0.06  
Univariate Analysis    
Matched for sex, DM,
and age. A key feature in
vasculature calcification
is the osteogenic
transition of SMCs miR
2861 might function as
an enhancer of
osteogenic
differentiation of SMCs.
The increased
circulating miR 2861
level may reflect CAC
progression.
 6 Han, et al.,2015 [15]
miR 21a
miR 23a
miR 34a
Up-
regulated:
miR 21
miR 23a
miR 34a
QRT-PCR Serum/Plasma
CAD vs Non-CAD
miR-34a, miR-21, and
miR-23a that are
differentially
expressed in CAD
plasma p=<0.01
Univariate Analysis
 7 Li, et al., 2013[16]  miR 526b
Up-
regulated:
miR 526b  
MiRNA by
KEGG  
Serum/
Plasma
Pre CAD vs Non-CAD
(Adjusted) miR 526b
p=0.00072,
p=0.003215
Univariate Analysis
CAD (UA) vs Non-
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 8 Ren, et al.,2013 [18]
miR 21 miR
25 miR 92a
miR 106b
miR 126
miR 451
miR 590/5p
Up-
regulated:
miR 21
miR 25
miR 92a
miR 106b
miR 126
miR 451
miR
590/5p
QRT-PCR Serum/Plasma
CAD (Adjusted) miR
21OR 2.488 95% CI
(1.173, 5.277) p=
<0.017 miR 25 OR
2.036   95% CI  (1.048,
3.955) p =<0.036 miR
92a OR 2.611 95% CI 
(1.110, 6.144) p =<
0.028 miR 106b OR
2.389 95% CI (1.158,
4.927) p= <0.018 miR
126 OR 1.882 95% CI
(1.140, 3.108) p =
<0.013 miR 126 OR
1.882 95% CI (1.140,
3.108) p =<0.013 miR
451 OR 4.609 95% CI
(2.171, 9.782) p =
<0.001 miR 5905p  OR
2.67895% CI (1.226,
5.849) p =<0.013
Adjusted for age, sex,
HTN, dyslipidemia, DM,
smoking status, and the
use of statins and anti-
platelet drugs)
 9 Guo, et al.,2012 [19]
miR 122
miR 370
Up-
regulated:
miR 122
miR 370
QRT-PCR Serum/Plasma
HLD+CAD vs Non-
CAD miR 122 OR 1.08
95 % CI 1.01–1.16 p =
0.034 miR 370  OR
1.05 95 % CI 1.01–1.12
p = 0.022
Adjustment for age,
gender, BMI, smoking,
HTN, DM, and blood
lipid profiles
 10
Sondermeijer,
et al.,2011
[21]
miR 340
miR 624
Up-
regulated:
miR 340
miR 624
QRT-PCR Platelets
Pre CAD vs Non-CAD
miR-340/ miR624 95%
CI: 0.59–0.83, p=
<0.002
Univariate Analysis
11
Fichtlscherer,
et al., 2010
[22]
miR 17 miR
92a miR
126 miR
133a miR
145 miR
155 miR
208a
Up-
regulated:
miR 133a
miR 208a  
     
QRT-PCR Plasma/Serum  
CAD vs Non-CAD
miR133a95% CI (5.22-
6.35,3.94-6.10) p=0.16
miR208a 95% CI(5.72-
6.74, 4.91-6.61) p=0.29
Univariate Analysis In
patients with stable
CAD, vascular-
derivedMiRNAs were
significantly down-
regulated, whereas
musclederivedMiRNAs
tended to be higher.
12 Hokestra, etal., 2010 [24]
miR 135
miR 147
Up-
regulated:
miR 135
QRT-PCR PBMCs  CAD vs Non-CAD miR135a p=<0.001 Univariate Analysis
Adjusted for age, sex,
culprit lesion, fasting
glucose, HbA1C, LDL
cholesterol, high-
sensitive CRP, and
history of HTN, DM, and
corrected CAD.  Marked
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13 Takahashi, etal., 2010 [25] miR146a/b
Up-
regulated:
miR146a/b
   
QRT-PCR PMBC CAD vs Non-CAD miR146a/b          p=<0.01
TLR4 expression in
atherosclerotic plaques,
oxidative stress
upregulates
macrophage TLR4
expression, perhaps an
association between
TLR4, inflammation and
coronary
atherosclerosis.
Activation of TLR4
signal may induce miR-
146a/b expression as a
negative regulator and
induce progression of
coronary
atherosclerosis.
14 Li, et al., 2010[26]
miR 21 miR
27b miR
130, miR
210
Up-
regulated:
miR 21
 miR 27b
miR 130
 miR 210
QRT-PCR
Vessel
Intima
and
Serum
AO vs Non-AO miR
21/27b/130/210 p=
<0.05
Univariate Analysis
15 Minami, et al.,2009 [27]
miR 221
miR 222
Up-
regulated:
miR 221
miR 222
QRT-PCR EP
Levels of miR 221 and
miR 222 were higher in
CAD group than in
non-CAD group
(p<0.01)
Univariate Analysis
TABLE 2: MicroRNA up-regulated studies
QRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction, CAD: Coronary Artery Disease, DM: Diabetes Mellitus,
HTN: Hypertension, TC: Total Cholesterol, TAG Triacylglycerols, HDL-c: High Density Lipoprotein Cholesterol, LDL-c: Low Density
Lipoprotein Cholesterol, AST: Aspartate Aminotransferase, ALT: Alanine Transaminase, LVEF: Left Ventricle Ejection Fraction, CK-
MB: Creatine Kinase Myocardial B fraction, LDH: Lactate Dehydrogenase, BMI: Body Mass Index, HLD : Hyperlipidemia, ACS:
Acute Coronary Syndrome, KEGG: Kyoto Engenomes, SMCS: Smooth Muscle Cells, HBA1C: Hemoglobin A1C, CRP: C-Reactive
Protein, TLR: Toll Like Receptor, AO: Arteriosclerosis Obliterans. EP: Endothetial Progenitor Cells, MP- Microparticles
Various different microRNA subtypes were studied with overlapping of the similar subtypes
across the studies. Sayed, et al. did two different studies in two different age groups namely 40-
60 and geriatric population. MicroRNA 756 was significantly up-regulated in both the middle-
aged and elderly with a potential to be considered as a non-invasive biomarker in this
population. Regulation of microRNA 223 was studied by Liu, et al. in 2015 and Diehl, et al. in
2012 in two case-control studies in China. Both the studies were not able to find a significant
relationship between CAD and MiR 223, respectively. MiR 21 upregulation was tested in three
of the studies: by Ren, et al. 2013, Diehl, et al., 2012 and Li, et al., 2010. Ren, et al. reported that
the relationship of MiR 21 to CAD had the OR 2.488 CI 95% (1.173-5.277) p =0.017, while Diehl,
et al. reported it to be p =0.042 and Li, et al. reported it to be p =0.05. MiR 92a and 126 were
under study by two authors, namely, Fichtlscherer, et al. (2010) and Ren, et al. (2013). Ren, et
al. reported that miR 92a and 126 when compared with CAD and non-CAD subjects had the OR
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2.611; CI 95% (1.110-6.144) p =0.028 and OR 1.882;CI 95% (1.140-3.108) p =0.013, respectively.
Fichtlscherer, et al. reported MiR 92a and 126 up-regulation had no significant relationship
with CAD when compared with non-CAD patients. MiR 146a was also studied by two authors
Takahashi, et al. and Diehl, et al. Both the authors were able to find a relationship of the up-
regulation of miR 146a. Lastly, miRNA 155 was also studied by two authors, namely,
Fichtlscherer, et al. and Diehl, et al. Neither studies found conclusive results for the
significance of this biomarker with CAD subjects when compared with non-CAD subjects.
Down-regulation and mircoRNA
A total of seven studies worked on the down-regulation of microRNA. All of the studies
employed QRT-PCR as the method of analysis for detection of microRNA. Three studies used
plasma as the source. Peripheral blood mononuclear cells were used by two studies. Two studies
used whole blood as the source and one study used pericardial fluid and coronary arteries
intima. All the studies reported down-regulation of microRNA in patients with CAD compared
with non-CAD patients. The adjusted parameters were same as the up-regulation studies used.
MicroRNA subtypes which overlapped in the reviewed studies are miR 149, miR 155, and miR
145. MicroRNA 149 was studied by Sayed, et al. in 2015, in two different studies on two
different age groups, which were 40-60 and a geriatric population. MicroRNA 149 was found to
be down-regulated in both middle-aged and the geriatric patients. MicroRNA 155 was studied
by four different authors namely, Hao, et al. 2014, Zhu, et al. 2014, Weber, et al. 2011 and
Fichtlscherer, et al. Hao, et al. [28] reported 95% CI (6.92±0.93, 5.08±1.55) p =0.017, Zhu, et al.
reported by Spearmen correlation analysis r =-0.663, p <0.001. Weber, et al. reported relation to
be significant with the p =0.002 while Fichtlscherer, et al. reported that there was no significant
relationship of microRNA 155 to CAD when compared to non-CAD patients (Table 3).
 
Name of
Author; Year
of Study  
MicroRNA
(miR or
miRNA)
MicroRNA:
Regulation
MicroRNA
Analysis Source
Strength of
Association (Odds
ratio, Relative Risk or
Regression Analysis)
Comments
1. Sayed, et al.,2015 [11]
miR149 miR
424 miR 765
Down Reg:
miR 149 miR
424    
QRT-PCR Serum/Plasma
Non-CAD vs. CAD
(Adjusted) miR149 95%
CI ( 0.894-0.983)
p=0.0001 miR 424 95%
CI (0.863-0.975)
p=0.0001 miR 765 95%
CI (0.939-0.996)
p=0.0001
Adjusted for age,
gender, TC, TG, HDL-C,
LDL-C, systolic blood
pressure, diastolic blood
pressure, AST, ALT,
creatinine, LVEF, DM,
smoking, HTN and
medications.
2. Sayed, et al.,2015 [12]
miR149 miR
765
Down Reg:
miR 149  QRT-PCR
Serum/
Plasma
CAD vs Non CAD
(Adjusted)  miR 149
p=0.001  
Adjusted for subjects
with similar age, gender,
total cholesterol, total
glyceride, HDL, LDL,
systolic blood pressure,
diastolic blood pressure,
AST, ALT, creatinine,
cardiac troponinI, CK-
MB, LDH, LVEF, DM,
smoking, HTN, and
medications.
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3. Zhu, et al.,2014  [16] miRNA 155
Down Reg:
miR 155    QRT-PCR PBMC
Correlation of miR-155
levels in PBMCs to
Gensini scores in all
patients (n=110).
Spearman correlation
analysis showed a
negative correlation
between miR-155
expression and the
Gensini score in all
patients; r = –0.663,
p=0.001.
Adjusted ( miR-155 was
correlated to multiple
metabolic and CAD RF,
including age, HTN, TC,
HDL-C, LDL-C,
Smoking, ACEI, statins,
and CRP, but not sex,
hereditary and DM or
Impaired Glucose
Tolerance.
4. Weber, et al.,2011 [20]
miR 19a miR
29a miR
30e/5p miR
145 miR 150
miR 155 miR
181d miR
222 miR 342
miR 378 miR
584
Down Reg :
miR 19a miR
29a miR
30e/5p miR
145 miR 150
miR 155 miR
181d miR 222
miR 342 miR
378 miR 584
QRT-PCR Wholeblood
CAD vs Non-CAD  miR
19a p= 0.012 miR
29a p=0.012  miR
30e/5p p= 0.02 miR 145
p= 0.008  miR 150 p=
0.006 miR 155 p=
0.002  miR 222 p=
0.001 miR 342 p=0.001 
miR 378 p= 0.001 miR
584 p= 0.036
Univariate Analysis   As
whole blood samples
were studied, thus
miRNA profile likely
reflects intracellular and
extracellular miRNAs
levels, in contrast to
exclusively extracellular
miRNAs that would be
detected in plasma.
5
Fichtlscherer,
et al., 2010
[22]
miR 17 miR
92a miR 126
miR 133a
miR 145 miR
155 miR
208a
Down Reg:
miR 17 miR
92a miR 126
miR 145 miR
155
QRT-PCR Plasma/Serum
CAD vs Non-CAD  
miR 17 95% CI(9.06-
10.97,5.42-8.29)
p=0.001 miR 92a 95%
CI (9.48-11.30,7.07-
9.75) p= 0.01 miR 126
95% CI (9.86-12.02,
6.21-9.03) p=0.001 miR
145 95% CI (3.87-5.57,
4.81-5.90) p= 0.16
Univariate Analysis In
patients with stable
coronary artery disease,
vascular-derived
miRNAs were
significantly down-
regulated, whereas
muscle derived miRNAs
tended to be higher.
6
Taurino,
et al., 2010
[23]
miR140/3p
miR182
Down Reg :
miR 140/3p
miR 182 miR
92a/b
QRT-PCR Wholeblood
CAD vs Non-CAD miR-
140-3p control vs. CAD
p=0.002 miR-182
control vs. CAD p=
0.001 miR-92a/b
control vs. CAD p=0.01
Univariate Analysis
7 Hoesktra, etal., 2010 [24]
miR 135 miR
147
Down Reg:
miR 147 QRT-PCR PBMC
CAD vs Non-CAD miR
147 p=<0.01 Univariate Analysis
TABLE 3: Down-Regulated microRNA studies
Reg: Regulated, QRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction, CAD: Coronary Artery Disease, DM:
Diabetes Mellitus, HTN: Hypertension, TC: Total Cholesterol, TAG: Triacylglycerols, HDL-c: High Density Lipoprotein Cholesterol,
LDL-c: Low Density Lipoprotein Cholesterol, AST: Aspartate Aminotransferase, ALT: Alanine Transaminase, LVEF: Left Ventricle
Ejection Fraction, CK-MB: Creatine Kinase for Myocardial B fraction, AP: Atherosclerotic Plaque, PBMC: Peripheral Blood
Mononuclear Cells, RF: Risk Factor, CRP: C-Reactive Protein, ACEI: Angiotensin Converting Enzyme Inhibitor
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Discussion
MiRNAs have been known to have an association with the physiological and pathological
processes involved in the development of CADs such as endothelial dysfunction, inflammation,
apoptosis, angiogenesis, atherosclerosis, and neointimal hyperplasia or restenosis [7,29-31].
Our systematic review summarizes 18 articles comparing miRNAs in CAD patients. Ten
studies found miRNAs that were up-regulated (21-3135b), five studies showed miRNAs that
were both up-regulated (21-765) and down-regulated (17-222), and three studies showed down-
regulated miRNAs (19a-584). miRNAs derived from plasma/serum, microparticles, whole blood,
platelets, blood mononuclear intimal and endothelial progenitor cells were investigated.
Circulating miRNAs (plasma or serum) exhibit remarkable stability and are highly resistant to
plasma ribonuclease (RNase) activity due to internalization in macro vesicles and the formation
of protein-miRNA complexes and can be used as a reliable marker for both the early diagnosis
and prognosis of CAD. Therefore, the levels of individual cardiac-enriched circulating miRNAs
are related to the diagnosis and prognosis of heart diseases. Recent studies have shown the
involvement of miRNAs in atherosclerosis, ranging from endothelial dysfunction to plaque
rupture suggesting the use of miRNA as potential biomarkers in early diagnosis of CAD [32].
miRNA upregulation or downregulation is either related to the atherosclerotic disease process
or the inflammatory compensation [21].
Sayed, et al. in elderly and Zhu, et al in middle-aged documented that miRNAs (149, 424 and
155, respectively) were down-regulated in CAD patients, Zhu, et al. postulated that miRNA 155
was downregulated because of the feedback mechanism that controls the overactivation of
immune cells and thus it is negatively correlated with coronary stenosis. Similarly,
Fichtlscherer, et al. found miRNA 155 to be downregulated in patients with CAD. Fichtlscherer
suggested that atherosclerotic lesions uptake circulating miRNAs, thereby decreasing their
levels in circulation and causing downregulation. miRNA 155 is noteworthy as it was found to
be downregulated in multiple studies which used different sources (serum plasma, whole blood,
and peripheral blood mononuclear cells (PMBC). Previously, Sondermeijer, et al. have reported
miRNA 624 and 340 to be down-regulated in the premature CAD patients [33].
Sayed, et al., Hoekstra, et al., and Ren, et al. showed an up-regulation of miRNA 765, 134-370
and 21-5905p, respectively, in the middle-aged population of unstable CAD patients as well.
Ren, et al. stated that miRNA (21-5905p) that are involved in the pathogenesis of vulnerable
plaque are mostly unregulated. In these patient populations, miRNA can be used as novel
biomarkers in the diagnosis of disease. The severity of the disease can be potentially seen by
aberrancy of miRNA in form of either up-regulation or down-regulation. Prior studies have
shown that the levels of miRNA are linked with disease severity. The up-regulated miRNA leads
to the evolution of plaque towards growth, instability, and rupture [33]. Fichtlscherer, et al. in a
prospective case control trial studied miRNA derived from endothelial, cardiac, skeletal, and
smooth muscle cells. Interestingly, in CAD patients endothelial and smooth muscle miRNAs
were up-regulated and in cardiac and skeletal muscle cells miRNA 133a/208a/155 were down-
regulated in the same patient population. Prior studies have also documented the differential
role of miRNA in skeletal, smooth and cardiac muscle [34]. The reason for this asymmetric
regulation is an uptake of miRNAs in cardiac muscles by atherosclerotic lesions in apoptotic
bodies and endothelial cells are exposed to inflammatory cells that can increase miRNA due to
cellular stressors (Fichtlscherer, et al). miRNA can be specifically monitored in certain disease
processes and used as prognostic markers as seen in CAD patients with diabetes, miRNA 145
being reduced compared to those without DM (Fichtlscherer, et al). For instance, Sondermeijer,
et al. showed that the platelet-derived miRNA can potentially fine-tune the expression of
specific gene products that may be involved in governing platelet reactivity. Therefore, a
dysfunctional miRNA-based regulatory system could lead to the development of serious
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platelet-related cardiovascular diseases (Sondermeijer, et al).
Studies by Zhou, et al. and Li, et al. in CAD patients reported an upregulation of plasma-derived
miRNA (140-3p/182, 206/574-5p, 134-3135b respectively). Taurino, et al. showed
downregulation of whole blood-derived miRNA 92-182 at the genetic level. Interestingly, Guo,
et al. and Minami, et al. in statin therapy CAD patients documented a significant
downregulation of miRNA 122/370 and 221/222 levels that were previously up-regulated.
Endothelial progenitor cells play an important level and in the regulation of miRNA after
treatment with lipid therapy on lipometabolism related miRNA (Minami, et al.). Similarly,
Takahashi, et al. noted a decrease in the miRNA 146 a-b levels in CAD patients in post-statin
and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy
as well. In a cross-sectional study by Weber, et al., miRNA 19a-584 was also reported to be
significantly down-regulated in CAD patients post ACE/ARB therapy. The response of miRNA to
medications may provide an insight into the prognostic value of miRNA. Pharmacological
therapy has been known to have an effect through gene signaling pathway, which further
influences miRNA levels [7]. Diehl, et al. examined microparticles derived miRNA 19-223 and
documented an upregulation in acute coronary syndrome (ACS) patients. Certain miRNA are
shown to be involved in cardiac hypertrophy and angiogenesis and shown to be up-regulated in
microparticles (Diehl, et al). Interestingly, Li, et al. observed upregulation of miRNA 21-210 in
the intima of arteriosclerosis obliterans (ASO) patients. miRNA has been shown to be pro-
angiogenic through its effects at the genetic level (Li, et al). 
Limitations
Firstly, criteria for CAD participant enrolment across the studies were not
standardized. Secondly, the study cohorts were not age and sex matched. Thirdly, the
population size of different trials was very small. Fourthly, none of the included studies
prospectively analyzed a specific miRNA regulation derived from one source or from different
sources. Even specific miRNA regulation can be varied when compared across different studies
and sources of origin. The pre and post CAD miRNA levels were not mentioned by any of the
studies. Large randomized double-blinded studies are needed to eliminate population bias and
increase the statistical power of each study. Prospective case-control trials with longer follow-
up periods may play a role in deciphering the prognostic potential for the miRNA markers in
CAD patients. Lastly, studies included did not mention specifically the number of patients on
ACE/ARBs or statins.
Conclusions
miRNA expression profile is associated with several human cardiovascular diseases, suggesting
their role as a novel class of biomarkers as well as potential treatment targets for cardiovascular
diseases. This systematic review provides a potential insight on miRNA regulations in subjects
with and without CAD and highlights the different parameters which could be the reason for
aberrant miRNA expression. Further understanding of miRNA expression may help to delineate
their role in improving both the diagnostic and therapeutic approaches to stratifying CAD
burden in the general population.
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